8月7日，派格生物医药-B盘中上涨8.93%，报5.805港元，成交额4175.36万港元。
消息面上，公司核心产品派达康（维培那肽注射液）已在北京大学人民医院、中南大学湘雅二医院等多家医疗机构开出全国首批商业化处方，腾瑞制药已确认将支付约4900万港元第二笔权益金。此前公司已收到首笔权益金6100万港元，商业化里程碑付款持续兑现。此外，公司已与腾瑞制药、阿里健康签署三方战略合作协议，加速打通线上线下商业化链路，产品放量蓄势待发。维培那肽注射液还已通过国家医保目录调整初步形式审查，后续医保准入工作有序推进。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.